Study of Quemliclustat and Chemotherapy Versus Placebo and Chemotherapy in Patients With Metastatic Pancreatic Ductal Adenocarcinoma
NCT06608927 · PRISM-1 Phase 3Active, not recruiting
- Lead sponsor
- Arcus Biosciences, Inc. (Industry)
- Enrollment
- 610 (estimated)
- Start date
- 13 Dec 2024
- Primary completion
- 30 Nov 2030 (estimated)
- Study completion
- 30 Nov 2030
- Last update posted
- 29 Sep 2026
Design
- Study type
- Interventional
- Primary purpose
- Treatment
- Allocation
- Randomized
- Intervention model
- Parallel
- Masking
- Quadruple
- Arms
- 2
Interventions
- Quemliclustat Drug
- Placebo Drug
- Nab-paclitaxel Drug
- Gemcitabine Drug
Conditions and primary outcome
- Metastatic Pancreatic Ductal Adenocarcinoma
Primary outcome
Overall Survival (OS) (Up to 72 months)
Posted results on ClinicalTrials.gov
Results posted on ClinicalTrials.gov: No
Results from company and journal sources
No editor-confirmed results are on record for this study.
Publications
No PubMed citation lists NCT06608927.
CT-VCA trial quality
About CT-VCALoading CT-VCA scores…
Data integrity
Compare what the registry, company releases, FDA documents and publications say about this study.
Drugs on HealthTrade
Source
- NCT06608927 on ClinicalTrials.gov (opens in a new tab) Licence: public-domain. Read
Source: ClinicalTrials.gov, U.S. National Library of Medicine. Listing a study does not mean NLM has evaluated it.
Nothing on this page is medical or investment advice.